Juergen Wolf

6.8k total citations
92 papers, 1.8k citations indexed

About

Juergen Wolf is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Juergen Wolf has authored 92 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 26 papers in Cancer Research. Recurrent topics in Juergen Wolf's work include Lung Cancer Treatments and Mutations (57 papers), Cancer Genomics and Diagnostics (24 papers) and Lung Cancer Research Studies (23 papers). Juergen Wolf is often cited by papers focused on Lung Cancer Treatments and Mutations (57 papers), Cancer Genomics and Diagnostics (24 papers) and Lung Cancer Research Studies (23 papers). Juergen Wolf collaborates with scholars based in Germany, United States and Switzerland. Juergen Wolf's co-authors include Volker Diehl, Enriqueta Felip, Johan Vansteenkiste, Michael Hallek, Daniel Shao-Weng Tan, Raymond Voltz, Jan Gaertner, Egbert F. Smit, Gregory J. Riely and Jan‐Peter Glossmann and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Juergen Wolf

85 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Juergen Wolf Germany	22	1.0k	914	630	334	282	92	1.8k
Ana C. Xavier United States	13	1.1k 1.0×	1.1k 1.2×	518 0.8×	197 0.6×	333 1.2×	51	1.8k
Katherine Liau United States	19	1.1k 1.1×	843 0.9×	861 1.4×	185 0.6×	441 1.6×	36	2.0k
Melanie Mackean United Kingdom	20	873 0.8×	469 0.5×	563 0.9×	233 0.7×	301 1.1×	48	1.7k
Giuseppe Lo Russo Italy	24	1.3k 1.2×	731 0.8×	567 0.9×	148 0.4×	371 1.3×	145	2.0k
J.-Y. Douillard France	15	1.0k 1.0×	891 1.0×	264 0.4×	252 0.8×	475 1.7×	59	1.8k
Parviz Hanjani United States	27	651 0.6×	440 0.5×	500 0.8×	282 0.8×	183 0.6×	59	2.4k
Karina Vera United States	10	723 0.7×	762 0.8×	816 1.3×	142 0.4×	287 1.0×	17	1.7k
Deepa Rangachari United States	22	1.1k 1.1×	1.3k 1.5×	459 0.7×	124 0.4×	430 1.5×	68	1.8k
Virginia L. Filiaci United States	26	505 0.5×	443 0.5×	461 0.7×	242 0.7×	214 0.8×	49	3.4k
Rachel N. Grisham United States	23	669 0.6×	236 0.3×	596 0.9×	236 0.7×	233 0.8×	119	1.7k

Countries citing papers authored by Juergen Wolf

Since Specialization

Citations

This map shows the geographic impact of Juergen Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Wolf more than expected).

Fields of papers citing papers by Juergen Wolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juergen Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Wolf. The network helps show where Juergen Wolf may publish in the future.

Co-authorship network of co-authors of Juergen Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of Juergen Wolf. A scholar is included among the top collaborators of Juergen Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juergen Wolf. Juergen Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scheel, Andreas H., Margaret Dugan, Robert Wild, et al.. (2024). Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score. npj Precision Oncology. 8(1). 259–259.

Fischer, Rieke, Julie George, Hans Anton Schloesser, et al.. (2024). BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMB^high cohort.. Journal of Clinical Oncology. 42(16_suppl). 8099–8099. 1 indexed citations

Barlési, Fabrice, Enriqueta Felip, Sanjay Popat, et al.. (2024). Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).. Journal of Clinical Oncology. 42(16_suppl). TPS8653–TPS8653. 4 indexed citations

Drilon, Alexander, Rafał Dziadziuszko, David Ross Camidge, et al.. (2024). Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.. Journal of Clinical Oncology. 42(16_suppl). 8522–8522.

Tan, Daniel S.W., Sang‐We Kim, Santiago Ponce Aix, et al.. (2022). Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study. European Journal of Cancer. 172. 276–286. 11 indexed citations

Subbiah, Vivek, Igor Puzanov, Jean‐Yves Blay, et al.. (2020). Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers. Cancer Discovery. 10(5). 657–663. 86 indexed citations

Tan, Daniel S.W., Natasha B. Leighl, Gregory J. Riely, et al.. (2020). Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. The Lancet Respiratory Medicine. 8(6). 561–572. 43 indexed citations

Dziadziuszko, Rafał, Egbert F. Smit, Urania Dafni, et al.. (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology. 14(6). 1086–1094. 107 indexed citations

Gärtner, Jan, et al.. (2019). Early Palliative Care: Pro, but Please Be Precise!. Oncology Research and Treatment. 42(1-2). 11–18. 20 indexed citations

10.

Heydt, Carina, Roberto Pappesch, Udo Siebolts, et al.. (2019). Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors. Journal of Molecular Diagnostics. 21(6). 971–984. 14 indexed citations

11.

Alidousty, Christina, Carina Heydt, Svenja Wagener‐Ryczek, et al.. (2019). Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology. Journal of Thoracic Disease. 11(S1). S3–S8. 4 indexed citations

12.

Wang, Shuhang, et al.. (2019). 2017–2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(5). 768–783. 46 indexed citations

13.

Michels, Sebastian, Jana Fassunke, Matthias Scheffler, et al.. (2016). Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: Results of the German Network Genomic Medicine.. Journal of Clinical Oncology. 34(15_suppl). 9085–9085. 2 indexed citations

14.

Thress, Kenneth S., Joseph Geradts, Martin Schüler, et al.. (2015). Design, execution, and preliminary biomarker results from paired tumor biopsy cohorts of the AZD9291 AURA trial. Journal of Thoracic Oncology. 1 indexed citations

15.

Rosell, Rafael, Niki Karachaliou, Juergen Wolf, & Sai‐Hong Ignatius Ou. (2014). ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. The Lancet Respiratory Medicine. 2(12). 966–968. 12 indexed citations

16.

Gaertner, Jan, Juergen Wolf, Sebastian Frechen, et al.. (2011). Recommending early integration of palliative care — does it work?. Supportive Care in Cancer. 20(3). 507–513. 34 indexed citations

17.

Gaertner, Jan, Juergen Wolf, Sebastian Frechen, et al.. (2010). Implementing WHO Recommendations for Palliative Care into Routine Lung Cancer Therapy: A Feasibility Project. Journal of Palliative Medicine. 13(6). 727–732. 26 indexed citations

18.

Nogová, Lucia, Thomas Zander, Theodore C. Pellas, et al.. (2007). P1-084: Mammalian target of rapamycin (mTOR) inhibition by RAD001 in patients (pts) with reccurent non-small cell lung cancer (NSCLC): Use of 18F fluorodeoxyglucose positron-emission tomography (FDG-PET) in evaluation of the pharmacodynamic effect. Journal of Thoracic Oncology. 2(8). S583–S583. 2 indexed citations

19.

Adam, Patrick, Tiemo Katzenberger, Harald Seeberger, et al.. (2003). A Case of a Diffuse Large B-Cell Lymphoma of Plasmablastic Type Associated With the t(2;5)(p23;q35) Chromosome Translocation. The American Journal of Surgical Pathology. 27(11). 1473–1476. 77 indexed citations

20.

Kornacker, Martin, Uwe Schlattner, Theo Wallimann, et al.. (2001). Hodgkin disease‐derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. International Journal of Cancer. 94(4). 513–519. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact